Clinical Trial Detail

NCT ID NCT01664182
Title Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

renal cell carcinoma


Sunitinib + Trebananib

Pazopanib + Trebananib

Sorafenib + Trebananib


Bevacizumab + Trebananib

Age Groups: adult

No variant requirements are available.